Atossa Genetics Inc

$0.92
(as of Jun 9, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Atossa Genetics Inc

Stock Price
$0.92
Ticker Symbol
ATOS
Exchange
NASDAQ

Industry Information for Atossa Genetics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Atossa Genetics Inc

Website
https://www.atossatherapeutics.com
Country
USA
Full Time Employees
15

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Fundamentals for Atossa Genetics Inc

Market Capitalization
$116,265,920
EBITDA
$-28,039,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.20
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
129,170,000
Percent Owned by Insiders
0.07%
Percent Owned by Institutions
26.58%
52-Week High
52-Week Low

Technical Indicators for Atossa Genetics Inc

50-Day Moving Average
200-Day Moving Average
RSI
57.07
ATR
0.07

Analyst Ratings for Atossa Genetics Inc

Strong Buy
1
Buy
2
Hold
0
Sell
0
Strong Sell
0

News About Atossa Genetics Inc

Apr 30, 2025, 8:45 AM EST
SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. See more.
Apr 29, 2025, 8:45 AM EST
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. See more.
Apr 22, 2025, 8:45 AM EST
SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. See more.
Mar 20, 2025, 9:13 AM EST
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. See more.